Heart Failure Reviews

, Volume 19, Issue 4, pp 541–551

Prediction of clinical outcomes using B-type natriuretic peptides in the general population: a systematic review

  • Andrew C. Don-Wauchope
  • Pasqualina L. Santaguida
  • Robert McKelvie
  • Judy A. Brown
  • Mark Oremus
  • Usman Ali
  • Amy Bustamam
  • Nazmul Sohel
  • Stephen A. Hill
  • Ronald A. Booth
  • Cynthia Balion
  • Parminder Raina
Article

DOI: 10.1007/s10741-014-9446-7

Cite this article as:
Don-Wauchope, A.C., Santaguida, P.L., McKelvie, R. et al. Heart Fail Rev (2014) 19: 541. doi:10.1007/s10741-014-9446-7

Abstract

The use of B-type natriuretic peptides to predict outcomes in general populations has been investigated in a number of primary studies. A previous systematic review considering natriuretic peptides in cardiovascular disease included a subgroup of general population studies, which suggested an association with a number of clinical outcomes. We electronically searched Medline, Embase, AMED, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and CINAHL for English-language articles published between 1989 and mid-2012. We utilized trained reviewers and standardized forms to screen articles for inclusion and extract data from included articles. All included studies (n = 7) were summarized in narrative and tabular form. A general population was defined as one that was randomly selected from a community setting where no specific inclusion or exclusion criteria were specified. The seven included studies all used FDA approved assays for NT-proBNP. The range of clinical outcomes and heterogeneity did not allow for meta-analysis. The hazard ratios for predicting outcomes in the included studies ranged from 1.0 to 4.1 (all p values <0.05). The discrimination statistics reported in four studies all demonstrated statistically significant improvements in predicting outcomes. NT-proBNP is associated with heart failure, all-cause and cardiovascular mortality, and other combined cardiovascular events in a general unselected population. The discrimination statistics suggest modest improvements in risk stratification. No prospective studies exist to demonstrate the clinical utility of using B-type natriuretic peptides to predict clinical outcomes in a general population.

Keywords

Natriuretic peptide General population Prognosis Discrimination statistics Systematic review 

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Andrew C. Don-Wauchope
    • 1
  • Pasqualina L. Santaguida
    • 2
  • Robert McKelvie
    • 3
  • Judy A. Brown
    • 2
  • Mark Oremus
    • 2
  • Usman Ali
    • 2
  • Amy Bustamam
    • 2
  • Nazmul Sohel
    • 2
  • Stephen A. Hill
    • 1
  • Ronald A. Booth
    • 4
  • Cynthia Balion
    • 1
  • Parminder Raina
    • 2
  1. 1.Department of Pathology and Molecular MedicineMcMaster UniversityHamiltonCanada
  2. 2.Department of Clinical Epidemiology and BiostatisticsMcMaster UniversityHamiltonCanada
  3. 3.Department of MedicineMcMaster UniversityHamiltonCanada
  4. 4.Department of Pathology and Laboratory MedicineUniversity of OttawaOttawaCanada

Personalised recommendations